Emanuele Noseda

A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Nicolino Ruperto, Pierre Quartier, Nico Wulffraat et al. · Arthritis & Rheumatism · 2011 · 191 citations

Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study

Andrea Chioato, Emanuele Noseda, Michael Stevens et al. · Clinical and Vaccine Immunology · 2012 · 69 citations · Full text

Influenza and Meningococcal Vaccinations Are Effective in Healthy Subjects Treated with the Interleukin-1β-Blocking Antibody Canakinumab: Results of an Open-Label, Parallel Group, Randomized, Single-Center Study

Andrea Chioato, Emanuele Noseda, SD Felix et al. · Clinical and Vaccine Immunology · 2010 · 39 citations · Full text

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

Nicolino Ruperto, Pierre Quartier, Nico Wulffraat et al. · Pediatric Rheumatology · 2008 · 18 citations · Full text

Immunology, Pharmacotherapy, Immunotherapy +24

A Phase II Study to Evaluate Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features

Nicolino Ruperto, Pierre Quartier, Nico Wulffraat et al. · 2012 · 14 citations

Immunodeficiencies, Phase Ii Study, Preliminary Safety +20